Key facts
- Bloom Science’s last known valuation is $46.0M.
- It has raised $23.0M; the latest was Later Stage VC ($11.0M) in Nov 2024.
- Notable investors include Impact Assets, Joyance Partners, ALS Investment Fund, Apollo Health Ventures, Leaps by Bayer — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Bloom Science
- ·The full record, as it builds
Funding rounds
No funding rounds for Bloom Science are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bloom Science
Developer of a biopharmaceutical company intended to advance microbe-based therapeutics for neurological disorders. The company offers a translation of the therapeutic benefit of the ketogenic diet into innovative medicines for serious, life-interrupting illnesses, enabling patients with epilepsy and other neurological conditions to receive proper medication and treatment.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 19
- Website
- bloomscience.com/
- Ownership
- Privately Held (backing)
Bloom Science doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bloom Science shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bloom Science in its N-PORT filings yet. We sweep new filings monthly.